Shares of Ligand Pharmaceuticals (NASDAQ:LGND) are up 135% in 2013. Despite this historic rise, the royalty collecting pharmaceutical company has plenty of room to run as it sees more drug approvals and returns cash to shareholders.
From the company's website:
"Ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. We operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders."
New Approval With Pfizer for Menopause
Earlier in the week, Ligand Pharmaceuticals saw a drug it shares with Pfizer (NYSE:PFE) approved...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|